| 2025年12月17日 申报日期:2025年12月19日 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Common Stock | 处置(D) | 148,153 | 11.00 | 1,629,683 推算:股数 × 每股价格。精确值 1629683.00。 | 0 | 间接(I) See Footnote | 否 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月19日 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 衍生证券: Prefunded Warrants — 标的 Common Stock (433,962) — 行权价 0.0001 | 处置(D) | 433,962 | 10.999 | 4,773,148.038 推算:股数 × 每股价格。精确值 4773148.038。 | 0 | 间接(I) See Footnote | 否 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月19日 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 衍生证券: Series A Common Stock Purchase Warrants — 标的 Common Stock (117,019) — 行权价 8.16 | 处置(D) | 117,019 | 4.71 | 551,159.49 推算:股数 × 每股价格。精确值 551159.49。 | 0 | 间接(I) See Footnote | 否 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月19日 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 衍生证券: Series C Common Stock Purchase Warrants — 标的 Common Stock (117,019) — 行权价 8.16 | 处置(D) | 117,019 | 4.71 | 551,159.49 推算:股数 × 每股价格。精确值 551159.49。 | 0 | 间接(I) See Footnote | 否 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月19日 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 衍生证券: Amended Series A Common Stock Purchase Warrants — 标的 Common Stock (158,531) — 行权价 0.01 | 处置(D) | 158,531 | 10.99 | 1,742,255.69 推算:股数 × 每股价格。精确值 1742255.69。 | 0 | 间接(I) See Footnote | 否 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月19日 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 衍生证券: Amended Series C Common Stock Purchase Warrants — 标的 Common Stock (250,627) — 行权价 0.01 | 处置(D) | 250,627 | 10.99 | 2,754,390.73 推算:股数 × 每股价格。精确值 2754390.73。 | 0 | 间接(I) See Footnote | 否 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,218) — 行权价 5.41 | 处置(D) | 1,218 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322642 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 4.45 | 处置(D) | 5,833 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322642 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,218) — 行权价 3.453 | 处置(D) | 1,218 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322642 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,479) — 行权价 5.41 | 处置(D) | 1,479 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322643 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (8,750) — 行权价 4.45 | 处置(D) | 8,750 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322643 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,291) — 行权价 3.453 | 处置(D) | 1,291 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322643 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,187) — 行权价 5.41 | 处置(D) | 1,187 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322641 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 4.45 | 处置(D) | 5,833 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322641 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,187) — 行权价 3.453 | 处置(D) | 1,187 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322641 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,250) — 行权价 5.41 | 处置(D) | 1,250 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322638 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 4.45 | 处置(D) | 5,833 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322638 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,250) — 行权价 3.453 | 处置(D) | 1,250 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322638 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,218) — 行权价 5.41 | 处置(D) | 1,218 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322639 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 4.45 | 处置(D) | 5,833 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322639 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,187) — 行权价 3.453 | 处置(D) | 1,187 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322639 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 5.51 | 处置(D) | 5,833 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322645 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,125) — 行权价 3.453 | 处置(D) | 1,125 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322645 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (17,291) — 行权价 5.27 | 处置(D) | 17,291 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322644 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (11,000) — 行权价 4.45 | 处置(D) | 11,000 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322644 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (64,840) — 行权价 5.27 | 处置(D) | 64,840 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322637 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (70,000) — 行权价 4.45 | 处置(D) | 70,000 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322637 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (17,291) — 行权价 5.27 | 处置(D) | 17,291 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322640 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (13,000) — 行权价 4.45 | 处置(D) | 13,000 | — | — | 0 | 直接(D) | 否 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322640 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 5.26 | 处置(D) | 5,833 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322646 读取自申报文件的XML 对此行提出异议 |
| 2025年12月17日 申报日期:2025年12月17日 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,155) — 行权价 3.453 | 处置(D) | 1,155 | — | — | 0 | 直接(D) | 否 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 打开申报文件 0001193125-25-322646 读取自申报文件的XML 对此行提出异议 |
| 2025年12月16日 申报日期:2025年12月17日 | Hill Malcolm R Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 处置(D) | 133 | — | — | 0 | 直接(D) | 否 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 打开申报文件 0001193125-25-322642 读取自申报文件的XML 对此行提出异议 |
| 2025年12月16日 申报日期:2025年12月17日 | GARNER CAM L Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 处置(D) | 2,330 | — | — | 0 | 间接(I) By Garner Investments, L.L.C. | 否 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 打开申报文件 0001193125-25-322643 读取自申报文件的XML 对此行提出异议 |
| 2025年12月16日 申报日期:2025年12月17日 | Brady Todd C Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 处置(D) | 27 | — | — | 0 | 直接(D) | 否 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 打开申报文件 0001193125-25-322639 读取自申报文件的XML 对此行提出异议 |
| 2025年12月16日 申报日期:2025年12月17日 | CARLSON MARILYN R. Officer: Chief Medical Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 处置(D) | 360 | — | — | 0 | 直接(D) | 否 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 打开申报文件 0001193125-25-322644 读取自申报文件的XML 对此行提出异议 |
| 2025年12月16日 申报日期:2025年12月17日 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 处置(D) | 15,509 | — | — | 0 | 直接(D) | 否 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 打开申报文件 0001193125-25-322637 读取自申报文件的XML 对此行提出异议 |
| 2025年12月16日 申报日期:2025年12月17日 | Kowieski Mark Officer: Chief Financial Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 处置(D) | 11,815 | — | — | 0 | 直接(D) | 否 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 打开申报文件 0001193125-25-322640 读取自申报文件的XML 对此行提出异议 |